A New York City, New York, London, U.K., and Carmel, IN based company developing artificial intelligence to increase efficiency between medical treatment and research by matching clinical trials with patients. Antidote.me was originally launched as TrialReach in 2010 and rebranded to Antidote.me in 2016.
The company uses a partner network made up of 300+ patient advocacy groups, health portals, bloggers, lab and data partners, and social media to refer patients to clinical trials. Its areas of therapeutic focus includes:
- Allergy and Immunology
- Arthritis
- Autoimmune
- Cardiology
- CNS
- Dermatology
- Gastroenterology
- IBS
- Liver disease
- Metabolic
- Ophthalmology
- Rare disease
- Renal
- Respiratory
Antidote Match is the core of Antidote.me' platform. The software works to match trials to patients. The software uses industry standard and custom-designed ontologies with their proprietary algorithms to explore patients eligibility for trials. Through the software, patient's can find studies based on the same indicators, and they can find information on the studies and scientists and treatments involved in the clinical trials.
During the COVID-19 pandemic, Antidote.me offered their Antidote Match platform for free in order to try and speed up the process of connecting possible patients to COVID-19 trials.
Timeline
Funding rounds
Antidote.me raises $11M in Venture Round, September 2017
Antidote.me raised $3.2M in Series A Funding Round
Antidote.me raises $13.5M in Series B Funding round - February, 2015
Antidote.me raised $1,200,000 in Venture Round - October, 2011
Antidote.me raised an undisclosed amount on in Venture Round, April 2016
People
Kathleen Freeman
Vice President of Business Development
Further reading
6 Ways Patients Can Find Clinical Trials Worldwide
Web
November 9, 2017
Antidote Technologies Inc - Company Profile and News
Web
Antidote Technologies raises $11M to speed development of trial matching platform
Jeff Lagasse
Web
September 7, 2017
Antidote Technologies Unveils Smart COVID-19 Clinical Trial Search to Speed Up Treatment and Vaccine Research Worldwide
Business Wire
Web
April 14, 2020
Antidote Technologies' Laurent Schockmel Recognized as a Top 40 Healthcare Transformer
markets.businessinsider.com
Web
March 21, 2019
New LRA and Antidote Technologies Study Finds Clinical Trial Participation by Minorities Lagging - Lupus Research
Lupus Research Alliance
Web
February 20, 2020
TrialReach Raises $13.5M Series B To Match Patients To Clinical Trials
Steve O'Hear
Web
February 5, 2015
